糖尿病多支病变血运重建后长期生存:FREEDOM随访研究
FREEDOM试验将1900例糖尿病合并多支冠状动脉病变患者随机分配至CABG或PCI-DES组,中位随访3.8年时CABG优于PCI-DES。FREEDOM Follow-On研究对943例患者延长随访至中位7.5年,发现CABG组全因死亡率显著低于PCI-DES组(18.3% vs 24.3%,HR 1.36,95%CI 1.07-1.74,P=0.01)。
要点
- 糖尿病多支病变患者,长期随访中CABG较PCI-DES降低全因死亡率
- 延长随访子集的全因死亡率差异未达统计学显著性(P=0.076)
- 临床决策时应考虑CABG作为糖尿病多支病变的优先血运重建策略
核心结论
- 在糖尿病合并多支冠状动脉病变患者中,长期随访显示CABG较PCI-DES降低全因死亡率。
研究设计与样本
- FREEDOM试验随机分配1900例糖尿病合并多支冠状动脉病变患者至PCI-DES或CABG组,背景为优化药物治疗。
- FREEDOM Follow-On研究邀请原试验中心和患者参与,最终25个中心(原140个中心)贡献943例患者(原队列49.6%),中位随访7.5年(范围0至13.2年)。
主要发现
- 整个随访期间1900例患者中共314例死亡(原试验204例,Follow-On研究110例)。
- PCI-DES组全因死亡率显著高于CABG组(24.3% [159例死亡] vs 18.3% [112例死亡];HR 1.36;95%CI 1.07-1.74;P=0.01)。
- 在943例延长随访患者中,PCI-DES组全因死亡率为23.7%(99例死亡),CABG组为18.7%(72例死亡)(HR 1.32;95%CI 0.97-1.78;P=0.076)。
临床怎么用
- 对于糖尿病合并多支冠状动脉病变患者,选择血运重建策略时应考虑CABG以改善长期生存。
局限性
- Follow-On研究仅纳入原试验140个中心中的25个中心、943例患者(原队列49.6%),可能存在选择偏倚。
- 延长随访子集的全因死亡率差异未达统计学显著性(P=0.076)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) trial demonstrated that for patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention with drug-eluting stents (PCI-DES) in reducing the rate of major adverse cardiovascular and cerebrovascular events after a median follow-up of 3.8 years. It is not known, however, whether CABG confers a survival benefit after an extended follow-up period. OBJECTIVES: The purpose of this study was to evaluate the long-term survival of DM patients with MVD undergoing coronary revascularization in the FREEDOM trial. METHODS: The FREEDOM trial randomized 1,900 patients with DM and MVD to undergo either PCI with sirolimus-eluting or paclitaxel-eluting stents or CABG on a background of optimal medical therapy. After completion of the trial, enrolling centers and patients were invited to participate in the FREEDOM Follow-On study. Survival was evaluated using Kaplan-Meier analysis, and Cox proportional hazards models were used for subgroup and multivariate analyses. RESULTS: A total of 25 centers (of 140 original centers) agreed to participate in the FREEDOM Follow-On study and contributed a total of 943 patients (49.6% of the original cohort) with a median follow-up of 7.5 years (range 0 to 13.2 years). Of the 1,900 patients, there were 314 deaths during the entire follow-up period (204 deaths in the original trial and 110 deaths in the FREEDOM Follow-On). The all-cause mortality rate was significantly higher in the PCI-DES group than in the CABG group (24.3% [159 deaths] vs. 18.3% [112 deaths]; hazard ratio: 1.36; 95% confidence interval: 1.07 to 1.74; p = 0.01). Of the 943 patients with extended follow-up, the all-cause mortality rate was 23.7% (99 deaths) in the PCI-DES group and 18.7% (72 deaths) in the CABG group (hazard ratio: 1.32; 95% confidence interval: 0.97 to 1.78; p = 0.076). CONCLUSIONS: In patients with DM and MVD, coronary revascularization with CABG leads to lower all-cause mortality than with PCI-DES in long-term follow-up. (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes [FREEDOM]; NCT00086450).
引用
- Farkouh ME, Domanski M, Dangas GD, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2018. PMID: 30428398. doi:10.1016/j.jacc.2018.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。